← All stories
Health, Longevity & Biohacking

Bipolar disorder patients can go seven days with zero sleep during manic episodes

Huberman Lab · The Science & Treatment of Bipolar Disorder | Huberman Lab Essentials · July 16, 2026
Bipolar disorder patients can go seven days with zero sleep during manic episodes
Huberman Lab
Huberman Lab
The Science & Treatment of Bipolar Disorder | Huberman Lab Essentials
"People who are in a manic episode can often go 7 days or more with zero sleep. And a key feature of this zero sleep is that they're not troubled by it. They are just going and going and going with no sleep, up all hours, shopping, talking, running, doing all sorts of different things, and it doesn't bother them that they're not sleeping."
Huberman describes one of the most extreme symptoms of bipolar manic episodes: patients can remain awake for a week or longer without distress, continuing high-energy activities throughout. This is a clinical diagnostic criterion and represents the severity of neural disruption in the disorder, which affects 1% of the population and carries 20-30 times greater suicide risk.

About this episode

Andrew Huberman, professor of neurobiology and ophthalmology at Stanford School of Medicine, delivers an in-depth examination of bipolar disorder, a serious psychiatric condition affecting approximately 1% of the population and carrying a 20 to 30 times greater risk of suicide. The episode distinguishes between bipolar I, characterized by extended manic episodes lasting seven days or more, and bipolar II, which involves shorter or less intense manic periods often accompanied by major depressive episodes. Huberman details the diagnostic criteria for mania, including distractibility, impulsivity, grandiosity, flight of ideas, agitation, complete absence of sleep for days without distress, and rapid pressured speech. The episode traces the remarkable discovery of lithium treatment by Australian psychiatrist John Cade, who observed fellow prisoners of war during World War II and conducted unconventional experiments with urine from manic patients injected into guinea pigs, ultimately isolating lithium as the therapeutic agent in 1949. Huberman explains that lithium works by suppressing inflammation, providing neuroprotection, and potentially preventing the progressive atrophy of neural circuits responsible for interoception that characterizes long-term bipolar disorder. He emphasizes that drug therapy, particularly lithium, remains essential and that talk therapy alone is rarely effective, though cognitive behavioral therapy and interpersonal social rhythm therapy can provide important support when combined with medication. The episode also explores emerging treatments like electroconvulsive therapy for treatment-resistant cases and examines supplement-based approaches including high-dose omega-3 fatty acids and inositol, which show some promise but should never replace pharmaceutical intervention. Huberman concludes by presenting research linking bipolar disorder and mania to creative professions, noting that 90% of eminent poets and 30% of exceptional actors in one study displayed mood disorders, suggesting that certain aspects of mania may correlate with creative output, though the disorder's maladaptive effects remain severe and life-threatening.

Key takeaways

More stories More from Huberman Lab